Paper Details

  1. Home
  2. Paper Details

Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study.

Author: AssiéJean Baptiste, BabeyHélène, ChouaïdChristos, CorreRomain, CortotAlexis, CurcioHubert, DecroisetteChantal, DescourtRenaud, DoubreHélène, FalcheroLionel, GuisierFlorian, HuchotEric, JammePhilippe, PérolMaurice, VeillonRemi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A retrospective study of 118 patients with advanced non-small cell lung cancer (aNSCLC) with MET exon 14 skipping mutations (METexon14) found no evidence of a benefit in overall survival (mOS) with anti-MET tyrosine kinase inhibitors (TKIs). The mOS was 27.1 months (95% CI 18-31.4) with a median follow-up of 16 months (95% CI 13.6-29.7).
Paper Details　
Original Abstract of the Article :
BACKGROUND: MET-targeted tyrosine kinase inhibitors (TKIs) demonstrated efficacy in advanced non-small cell lung cancer (aNSCLC) with MET exon14 skipping mutations (METexon14); yet, data on the management of these patients in clinical practice is sparse. OBJECTIVE: The aim of this study was to desc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s11523-023-00976-4

データ提供：米国国立医学図書館（NLM）

MET Exon14 Skipping in Non-Small Cell Lung Cancer: A Real-World Perspective

This research investigates the effectiveness of MET-targeted tyrosine kinase inhibitors (TKIs) in treating advanced non-small cell lung cancer (aNSCLC) with MET exon14 skipping mutations. Imagine a vast desert landscape with a hidden oasis, representing a specific genetic mutation that drives the growth of lung cancer. Researchers are exploring the potential of MET TKIs to reach this oasis and combat the disease effectively.

Real-World Treatment Outcomes for a Specific Genetic Mutation

This research delves into the real-world effectiveness of MET TKIs in aNSCLC patients with a specific genetic mutation, like a traveler seeking a specific oasis in a vast desert. The researchers analyzed data from a real-world setting, providing valuable insights into the clinical management of these patients.

Navigating the Desert of Lung Cancer Treatment

This research provides valuable insights into the clinical management of aNSCLC patients with specific genetic mutations, like a traveler seeking a specific path through a complex desert. The authors' findings highlight the importance of understanding the real-world effectiveness of different treatment options.

Dr. Camel's Conclusion

This research is like a journey through a desert landscape, where the goal is to find the most effective treatment for a specific type of lung cancer. The authors' findings highlight the importance of understanding the real-world effectiveness of MET TKIs and the need for further research in this area. This research reminds us that even in the most challenging of landscapes, there is always hope for finding a path towards healing.
Date :
  1. Date Completed 2023-07-17
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

37310660

DOI: Digital Object Identifier

10.1007/s11523-023-00976-4

Related Literature

Article Analysis
・Effects of capmatinib・Effects of tepotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.